Deutsche Bank has upgraded AI infrastructure provider CoreWeave to 'Buy,' significantly raising its price target to $140, citing a strong medium-term outlook and capacity expansion plans backed by a deepened partnership with Nvidia.
Ovid Therapeutics (NASDAQ: OVID) has garnered analyst optimism following positive Phase 1 trial results for its novel neurological drug candidate and a recent 'Outperform' initiation. The biotech firm is now shifting focus to a more potent oral therapy, with key regulatory milestones ahead.
Piper Sandler raises its price target for Century Therapeutics (IPSC), highlighting the biotech firm's robust financial position extending into 2029 and an upcoming Investigational New Drug application for its lead cell therapy candidate, CNTY-813.
Citi raises Lexicon Pharmaceuticals' price target to $2.10, citing strong momentum from its collaboration with Novo Nordisk on obesity drug candidate LX9851 and improved financials.
A mixed third-quarter earnings season for therapeutics stocks reveals divergent paths, with United Therapeutics missing estimates while peers like Halozyme and Biogen post strong beats. Sector-wide revenue growth and positive stock reactions suggest underlying investor confidence despite regulatory and pricing headwinds.
Barclays' upgrade of PTC Therapeutics to Overweight has spotlighted the biotech firm's valuation, with shares showing strong momentum but questions lingering over its path to profitability and reliance on a narrow drug portfolio.
While rising crude prices have lifted Occidental Petroleum's stock recently, a mixed earnings performance and a predominantly 'Hold' rating from Wall Street signal lingering skepticism about its near-term trajectory.
Amneal Pharmaceuticals' shares have surged over 64% in the past year, prompting investors to question if the rally still has room to run. A closer look at valuation metrics suggests the generic drugmaker may still be trading at a significant discount to its intrinsic value.
Shares of Corcept Therapeutics plunged 16% after a corrected FDA letter disclosed the agency had repeatedly cautioned the company against filing its application for a Cushing's syndrome drug, which was later rejected over efficacy and safety concerns.
The United States, in coordination with European allies, has imposed new sanctions on Iran's Interior Minister and other officials, accusing them of orchestrating a violent suppression of nationwide protests. The measures target assets and travel, reflecting a widening international response to Tehran's handling of domestic unrest.
Bitmine Immersion Technologies faces heightened scrutiny following the sudden departure of its president and a strategic pivot that has seen it amass over 3.5% of all Ethereum. Analysts question the dual risks of management instability and extreme asset concentration as the stock shows recent volatility.
European Commission Vice President Teresa Ribera voices profound shock at the fatal shootings of two protesters in Minneapolis, contrasting with the EU's official cautious stance. Her remarks come as transatlantic tensions simmer over U.S. immigration policies and recent geopolitical threats.
The head of the European Stability Mechanism has told Reuters the bloc's 430-billion-euro emergency fund could be repurposed to provide defense loans to member states, signaling a strategic shift as Europe seeks to bolster its military autonomy.
Denmark's government announced a bold legislative package aimed at expanding deportations and tightening immigration controls, setting the stage for a potential clash with the European Court of Human Rights.
Bank of America has increased its price target for industrial packaging firm Greif (GEF) by $1 to $75, while reiterating a Neutral rating. The adjustment follows the bank's broader reassessment of the packaging sector after recent quarterly earnings calls.
LifeSci Capital reaffirms its Buy rating on Olema Pharmaceuticals (OLMA) and raises its price target to $45, following bullish analyst sentiment on the company's lead drug candidate, Palazestrant, for ER+/HER2- breast cancer.
CIBC reaffirms its Outperform rating on Thomson Reuters (TRI) as the information giant accelerates its strategic push into AI-driven compliance and legal tools, launching new products in the US and UK markets.
Europe relies on China for the rare earth elements essential in transition technologies, but it's making a late bid to end dependency.
Deutsche Bank's 2025 net profit nearly doubled to €7.1bn, fueled by revenue gains and cost cuts across all divisions, even as German prosecutors launch a money-laundering investigation linked to the lender.
The Eurozone economy expanded by 1.5% in 2025, outpacing forecasts despite ongoing trade tensions with the US, as a recovery in Germany and robust growth in Spain helped offset a slowdown in France.
